Johnson & Johnson (NYSE:JNJ) Shares Sold by Adirondack Trust Co.

Adirondack Trust Co. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 23,862 shares of the company’s stock after selling 933 shares during the period. Johnson & Johnson makes up approximately 1.3% of Adirondack Trust Co.’s investment portfolio, making the stock its 16th biggest position. Adirondack Trust Co.’s holdings in Johnson & Johnson were worth $3,451,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Dark Forest Capital Management LP acquired a new position in Johnson & Johnson during the 2nd quarter worth $223,000. Peloton Wealth Strategists lifted its position in shares of Johnson & Johnson by 3.1% during the 2nd quarter. Peloton Wealth Strategists now owns 16,749 shares of the company’s stock worth $2,448,000 after purchasing an additional 496 shares during the last quarter. Texas Capital Bancshares Inc TX lifted its holdings in Johnson & Johnson by 26.3% during the 2nd quarter. Texas Capital Bancshares Inc TX now owns 5,268 shares of the company’s stock worth $770,000 after buying an additional 1,096 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Johnson & Johnson by 25.6% in the second quarter. Texas Capital Bank Wealth Management Services Inc now owns 4,997 shares of the company’s stock valued at $730,000 after purchasing an additional 1,019 shares in the last quarter. Finally, Bontempo Ohly Capital Mgmt LLC grew its position in shares of Johnson & Johnson by 0.8% in the 2nd quarter. Bontempo Ohly Capital Mgmt LLC now owns 14,650 shares of the company’s stock valued at $2,141,000 after buying an additional 115 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. Bank of America decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.06.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $146.76 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $353.34 billion, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. The company has a 50-day moving average price of $147.85 and a two-hundred day moving average price of $155.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $2.29 earnings per share. Analysts forecast that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.